Two phase III studies with tamsulosin, a selective a 1A -adrenergic receptor antagonist, were conducted to evaluate the safety and efficacy of the standard treatment doses of 0.4 mg/day and 0.8 mg/day in patients with symptoms of benign prostatic hyperplasia (BPH). These large-scale clinical trials were the first to include extensive testing for possible druginduced orthostatic hypotension (OH). The frequency of positive orthostatic tests and magnitude of vital sign changes were compared among tamsulosin and placebo-treated groups. The results indicate that tamsulosin up to 0.8 mg/day does not induce higher risk of OH than that of placebo. Data from post-marketing surveillance (PMS) studies of tamsulosin indicate that the incidence of hypotension and syncope is extremely low in community-dwelling elderly men treated for BPH. From the results of the phase III studies, PMS studies and an activecontrolled clinical pharmacology study, we conclude that the orthostatic test is a useful and convenient method to evaluate the risk of OH and syncope during the investigational stage.
Introduction
Tamsulosin hydrochloride is a potent α 1Aadrenergic receptor antagonist used for the treatment of benign prostatic hyperplasia (BPH), a non-malignant condition that results in proliferation of the stromal/epithelial cells of the prostate gland and produces symptoms such as dysuria, urinary retention, urinary obstruction and urgency.
Clinical manifestations of BPH start in men in their late 40s. One study reported that one in every five men aged 40 -64 years, and two in every five men over 65 years old have prostate gland weight above the normal maximum of 20 g, symptoms of urinary dysfunction and/or maximum urinary flow rate below the normal maximum rate 15 ml/s. 1 The prevalence of BPH increases with age, and at least 90% of men aged 70 -90 years show some symptoms. 2 Tamsulosin acts by antagonizing the α 1A -adrenergic receptor, the predominant α-receptor subtype in the prostate, prostatic capsule, prostatic urethra and bladder neck, 3 -7 which results in localized smooth K Yasukawa, H Swarz, Y Ito Safety of tamsulosin in orthostatic hypotension muscle relaxation, improved urinary flow rate and reduced symptoms of BPH. 8 -16 The clinical usefulness of tamsulosin has been confirmed and it has been approved by 58 countries and marketed in 54 worldwide, including the USA. 17, 18 Orthostatic hypotension (OH) is a decline in systolic and diastolic blood pressure, often accompanied by increased pulse rate (PR), resulting from an impaired haemodynamic response to adopting an upright posture. 19 The clinical symptoms most commonly reported by patients with OH on assumption of an upright posture include lightheadedness, weakness, impaired cognition, visual blurring, tremulousness and vertigo. 20 Falling, unsteadiness, syncope, palpitation, angina pectoris, calf claudication, headaches, paracervical pain and lower back pain have also been reported. 21 -24 However, it is not clear to what extent OH is a contributory factor to these symptoms. A high prevalence of OH has been reported among older patients with syncope, 25 but this may be an incidental effect reflecting the age of this population, since OH is a common finding among the elderly. 26 OH could be an otherwise benign condition that might contribute to syncope in patients with concomitant disorders. 25 Marked OH has been associated with conventional α 1 -antagonists, such as prazosin, terazosin and doxazosin, 9,27 -33 which were originally developed as anti-hypertensive agents but are used in the treatment of BPH. The incidence of OH with prazosin and terazosin reported in the US package inserts is 1 -4% 34 and 3.9% (versus 0.8% for placebo; P ≤ 0.05), 35 respectively, and in one placebocontrolled study with terazosin the reported incidence was 2 -8%. 36 For doxazosin, the US package insert reports a 1.7% incidence of hypotension, compared with 0% for placebo. This difference is statistically significant (P ≤ 0.05). 37 These agents must be titrated to the recommended therapeutic dose to avoid marked hypotension and syncope which are often observed after the first dose or when the dose is increased. Each time therapy is interrupted for any reason, patients must repeat the titration steps, and it may take 4 -6 weeks until the patients can receive the therapeutic dose.
However, since tamsulosin has high affinity for the α 1A -adrenoceptor, which is not present among the α 1 -adrenoceptors in the blood vessels, it was hypothesized that the therapeutic dose of tamsulosin for BPH would produce fewer cardiovascular side-effects and be associated with less OH. 9, 33 In order to prove this hypothesis, extensive orthostatic testing was performed in patients during two large-scale, placebo-controlled, phase III clinical trials of tamsulosin, US92-03A and US93-01. 13, 15 Orthostatic testing consists of measuring the patient's blood pressure and PR after 5 min in the supine position, immediately on standing, and again after the patient has been standing for 2 -3 min. However, the optimal criteria for a positive orthostatic test have not been established. The most common criteria for a positive test are a reduction in systolic blood pressure (SBP) of ≥ 20 mmHg or in diastolic blood pressure (DBP) of ≥ 10 mmHg on standing compared with supine levels, increase in PR of > 20 beats per minute (bpm) on standing compared with supine PR or symptoms of faintness, lightheadedness or dizziness on standing. 21 To the authors' knowledge, US92-03A and US93-01 are the only phase III clinical trials that included orthostatic testing as part of a drug safety study. 13, 15 This report presents the results of the orthostatic testing obtained in these two phase III trials, and demonstrates the applicability of the orthostatic test as a tool to evaluate the safety of an investigational drug in future clinical trials.
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Patients and methods
Two multicentre, placebo-controlled, doubleblind, phase III clinical trials, US92-03A and US93-01, were carried out in the USA between 1992 and 1993 to investigate the safety and efficacy of tamsulosin 0.4 mg or 0.8 mg once daily. Both trials included extensive orthostatic testing. 13, 15 The trials were open to men aged ≥ 45 years with signs and symptoms of BPH, based on score ≥ 13 on an American Urological Association (AUA) questionnaire on symptoms of BPH, 38 peak urine flow rate ≥ 4 and ≤ 15 ml/s (Urodyn™ 1000, Dantec Measurement Technology A/S, Skovlunde, Denmark) with a total urine volume of 125 ml and post-void residual urine volume < 300 ml (measured by abdominal ultrasound). Patients were excluded if they had repeated positive orthostatic tests previously, as were those with a history of syncope or a pathological fall that had occurred within 1 year prior to screening. Hypertensive patients were allowed to participate in the study unless they were already receiving treatment with an α-antagonist or other medication that could affect the study outcome.
There was a 4-week, single-blind, placebo evaluation period, during which patient eligibility for the study and protocol compliance were assessed at three clinic visits. On completion of the evaluation period, patients were independently randomized to one of three 13-week administration groups: tamsulosin 0.4 mg/day; tamsulosin 0.4 mg/day for 1 week followed by tamsulosin 0.8 mg/day; or placebo. Placebo was identical to the tamsulosin 0.4-mg capsule. Dose increase in the tamsulosin 0.8-mg group was performed regardless of the response and tolerability of patients.
In US92-03A, after receiving the first randomized test agent, patients remained at the study centre for an 8-h observation period, when clinical status, response to therapy, vital signs, orthostatic response and electrocardiograms were monitored. 13 Subsequent visits to the study centre for safety and efficacy tests were scheduled at 1, 2, 4, 7, 10 and 13 weeks.
In US93-01, patients did not remain in observation after the first randomized test agent was administered, and were scheduled to return to the study centre 1, 2, 5, 9 and 13 weeks after the first dose. 15 Orthostatic testing was performed at each visit in both studies. In a pharmacokinetic study of tamsulosin in the target population, plasma levels peaked 4 -8 h after post-prandial dosing. 39 In US92-03A, therefore, testing was performed prior to and 4 h and 8 h after the initial dose of study agent, and at 4 -8 h after dosing at subsequent visits. In US93-01, orthostatic testing was performed once during each visit. During the first two visits of the double-blind treatment period, orthostatic testing was performed 4 -8 h post-dose, i.e. at about the expected peak plasma concentration; and during the next three visits at 24 -27 h post-dose, at around the lowest plasma concentration ( Fig. 1 ).
ORTHOSTATIC TESTING AND POSITIVE CRITERIA
Orthostatic testing was performed by measuring blood pressure and PR after each patient rested quietly in the supine position for 5 min and again after a further 3 min quiet standing. Arterial blood pressure was measured with a mercury sphygmomanometer, using a large cuff if arm circumference exceeded 32 cm on the first visit. The same arm of each patient and the same cuff size were used throughout the study. The fifth-phase Korotkoff reading was recorded as diastolic arterial pressure. Pressures ending in 0.5 mmHg were rounded up to the next whole number, and a DBP of < 60 mmHg or PR > 110 bpm was confirmed by a repeat measurement.
Study subjects were deemed to have a K Yasukawa, H Swarz, Y Ito Safety of tamsulosin in orthostatic hypotension positive orthostatic test if they met one of the criteria listed in Table 1 . Each patient's pretreatment orthostatic test result was used as the baseline against which to evaluate results of orthostatic tests performed on the first day of administration of the agents (when patients in the tamsulosin 0.8-mg group received a 0.4-mg dose).
After the results of US92-03A and US93-01 had been obtained, clinically significant OH was defined, to investigate clinically meaningful changes further. This was in line with the results of the study by Atkins et al., 25 who suggest that 20 -30% of subjects > 65 years of age show a decline in SBP ≥ 20 mmHg on standing, and the report by Schatz 40 that the diagnosis of OH should be based on simultaneous blood pressure reduction and occurrence of clinical symptoms.
Clinically significant OH was defined according to criteria listed in Table 2 , and the incidence of clinically significant OH was investigated to assess each patient's risk of more severe side-effects, such as syncope or falling. 
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STATISTICAL ANALYSIS
Differences in the incidence of positive orthostatic tests among the three groups were determined using Fisher's exact test.
Results
BASELINE CHARACTERISTICS
In US92-03A, 756 patients were randomized to the two treatment groups or placebo ( Table 3) . All received at least one dose of a study agent and were evaluable. One hundred and thirty eight dropped out during the double-blind period. The mean ages of patients were 57.3, 59.0 and 59.5 years in the tamsulosin 0.4-mg group, tamsulosin 0.8-mg group and placebo group, respectively. In US93-01, 735 patients were randomized to the two treatment groups or placebo, and 731 received at least one dose of a study agent while 104 dropped out during the double-blind period ( Table 4 ). The mean ages of patients were 58.6, 58.3 and 58.1 years in the tamsulosin 0.4-mg, tamsulosin 0.8-mg and placebo groups, respectively. In both studies the number of dropouts was distributed equally among the three groups. Final test results during the placebo run-in period were used as baseline values during the treatment period.
US92-03A: FIRST TEST AGENT ADMINISTRATION
The mean change in SBP during orthostatic tests performed on the first day of administration of the test agents ranged from -4 mmHg (tamsulosin 0.4-mg group) to +1.8 mmHg (placebo group), while that in DBP ranged from +1.0 mmHg (tamsulosin 0.8-mg group) to +2.4 mmHg (placebo group). Increases in PR ranged from +4.6 bpm (placebo group) to +6.5 bpm (tamsulosin 0.4-mg group).
Two per cent (five of 247) of subjects in the tamsulosin 0.8-mg group, 7% (17/254) in the tamsulosin 0.4-mg group and 2% (five of 254) in the placebo group met one of the criteria for a positive orthostatic test prior to administration of the test agent (Table 1) . 
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There was thus a statistically significant (P = 0.009) difference among the three groups, due mainly to a difference in the number of patients who met the first criterion (tamsulosin 0.8-mg group, 1%; tamsulosin 0.4-mg group, 5%; placebo group, 2%).
Since the baseline results of the groups were biased, we investigated the orthostatic test results 4 h and 8 h after the first dose of test agent was given to patients with positive baseline tests, to facilitate assessment of the results after administration ( Table 5 ). The orthostatic test results 4 h and 8 h after administration were negative in all patients who were positive at baseline in the placebo group and tamsulosin 0.8-mg group. However, in the tamsulosin 0.4-mg group, six of 17 patients positive at baseline were also positive at 4h and 8 h. We concluded that it would be appropriate to evaluate the results after making a correction for the findings in the six patients given tamsulosin 0.4 mg who displayed positive reactions to orthostatic tests that were not associated with test drug administration.
The percentage of patients who met one criterion for a positive orthostatic test (Table 1 ) 4 h after the first administration was significantly higher in both tamsulosin groups than in the placebo group (7% in the tamsulosin 0.8-mg group, 8% in the tamsulosin 0.4-mg group and 3% in the placebo group; P = 0.04). The difference was mainly due to the criterion of a reduction in DBP (six patients in the tamsulosin 0.8-mg group, four patients in the tamsulosin 0.4-mg group and one patient in the placebo group). This criterion was not the same as the one that showed a difference in frequency among the three groups measured before treatment (i.e. reduction in SBP).
The percentage of patients who met one of the criteria for a positive orthostatic test at 8 h after study agent administration was 7% in the tamsulosin 0.8-mg group, 6% in the tamsulosin 0.4-mg group and 4% in the placebo K Yasukawa, H Swarz, Y Ito Safety of tamsulosin in orthostatic hypotension group. The percentage was slightly higher in the tamsulosin groups than in the placebo group, but was not statistically significant.
No patient displayed simultaneous positive orthostatic test criteria 1 and 4. One 46-year-old patient in the tamsulosin 0.4-mg group met criterion 2 for clinically significant OH (Table 2 ) 8 h after administration since he was unable to remain standing due to dizziness. The dizziness continued for 30 min but resolved without intervention.
In summary, after the first administration, a slightly higher percentage of patients in the tamsulosin groups met the criteria for a positive orthostatic test compared with the placebo group, but the difference was 0 -4% for each criterion, which is not statistically significant. In approximately 1000 orthostatic tests performed on tamsulosin-dosed patients, only one incident categorized as clinically significant OH was observed.
US92-03A: TREATMENT PERIOD
The final orthostatic test results obtained during the placebo evaluation period were used as the baseline for evaluation of the results obtained during the double-blind treatment period. No statistical difference in the incidence of positive orthostatic tests was observed among the groups.
At subsequent visits, the percentage of patients who met the first positive orthostatic test criterion (Table 1) was 2 -3% in the tamsulosin 0.8-mg group, 0 -3% in the tamsulosin 0.4-mg group and 1 -3% in the placebo group (Fig. 2) . There was no statistically significant difference among the groups. The mean change in supine to standing SBP was +1.0 -+2.5 mmHg in the tamsulosin 0.8-mg group, +1.6 -+3.1 mmHg in the tamsulosin 0.4-mg group and +2.4 -+3.5 mmHg in the placebo group. The differences among the groups were not statistically significant at any visit.
The percentage of patients who met the second positive criterion (Table 1) was < 1% in all groups throughout the study and there was no statistically significant difference among the groups. The mean change in supine to standing DBP was +2.1 -+3.1 mmHg in the tamsulosin 0.8-mg group, +2.3 -+4.0 mmHg in the tamsulosin 0.4-mg group and +2.7 -+4.1 mmHg in the placebo group. 
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In the tamsulosin 0.8-mg group 1 -2% met the third positive orthostatic test criterion (Table 1) , and corresponding percentages were < 2% in the tamsulosin 0.4-mg group and < 1% in the placebo group. The mean change in supine to standing PR at each visit was +4.8 -+6.0 bpm, +4.7 -+6.1 bpm and +3.9 -+5.7 bpm in the tamsulosin 0.8-mg group, tamsulosin 0.4-mg group and placebo group, respectively. There were some statistically significant differences in the mean results but the magnitude of the differences was less than 2 bpm, therefore no clinically meaningful differences were considered to have occurred among the groups. Only one patient in the tamsulosin 0.8-mg group met the fourth positive orthostatic test criterion during the study.
In the tamsulosin 0.8-mg group, 3 -4% of patients met one of the criteria for a positive orthostatic test during the treatment period (baseline 2%), as did 1 -4% in the tamsulosin 0.4-mg group (baseline 2%) and 1 -3% (baseline 2%) in the placebo group (Fig. 3) . No statistically significant differences in the number of positive orthostatic tests was detected among the groups at any study centre visit.
Of the patients who received tamsulosin 0.4 mg for 1 week prior to receiving tamsulosin 0.8 mg, 3% met one of the criteria for a positive orthostatic test prior to dose increase, compared with 3% at the visit 1 week after dose increase and 3 -4% thereafter until completion of the study. Increasing the tamsulosin dose from 0.4 mg to 0.8 mg was not considered to affect the number of patients who met the criteria for a positive orthostatic test. An adverse event categorized as OH was recorded for one 58-year-old patient in the tamsulosin 0.8-mg group on days 3 and 4 of administration, when the tamsulosin dose was 0.4 mg. This met criterion 3 for clinically significant OH (Table 2 ) and the patient was withdrawn from the study. Another patient in the tamsulosin 0.8-mg group, who displayed a reduction in SBP of 26 mmHg accompanied by dizziness on day 61 of administration, met criterion 1 for clinically significant OH (Table 2) . This patient was not withdrawn from the study.
US93-01
No bias was observed between the tamsulosin and placebo groups for any Week (n)
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positive orthostatic test criterion at baseline ( Table 6) .
The percentage of patients who met the first positive orthostatic test criterion (Table 1) was 1 -4% in all groups throughout the treatment period (Fig. 4 ). There were no statistically significant differences in frequency of the first positive orthostatic test criterion among the groups, except between the tamsulosin 0.8-mg group (then receiving the 0.4-mg dose) and the placebo group at visit 4, the first visit after 
Week (n) initiation of the double-blind treatment period (4% versus 1%). The mean change in supine to standing SBP in all three groups throughout the study period was +0.1 -+4.7 mmHg, which was not considered to be clinically meaningful. The mean change in supine to standing SBP during the baseline orthostatic test was +2.9 mmHg, +2.5 mmHg and +2.8 mmHg in the tamsulosin 0.8-mg group, tamsulosin 0.4-mg group and placebo group, respectively. There were no statistically or K Yasukawa, H Swarz, Y Ito Safety of tamsulosin in orthostatic hypotension clinically significant differences among the groups. The mean change in SBP associated with the orthostatic tests during the treatment period was +0.7 -+1.8 mmHg, +0.1 -+1.9 mmHg and +1.5 -+4.7 mmHg in the tamsulosin 0.8-mg group, tamsulosin 0.4-mg group and placebo group, respectively. During the double-blind period there was a statistically significant difference in supine to standing SBP at week 2 (+3.6, +3.7 and +1.9 mmHg for the tamsulosin 0.8-mg group, tamsulosin 0.4-mg group and placebo group, respectively; P = 0.055), week 5 (+0.7, +1.9 and +3.6 mmHg, respectively; P = 0.006) and week 9 (+1.8, +0.1 and +3.4 mmHg, respectively; P < 0.001), but no clinically meaningful changes in SBP associated with orthostatic tests were observed. No differences in supine to standing SBP at peak plasma level (visits 4 and 5) and lowest plasma level (visits 6, 7 and 8) were observed between the tamsulosin groups.
Less than 1% of patients in all three groups met the second positive orthostatic test criterion (Table 1) throughout the treatment period. There was no statistically significant difference among the groups. The mean change in DBP during the baseline orthostatic test was +4.4 mmHg, +4.2 mmHg and +3.8 mmHg in the tamsulosin 0.8-mg group, tamsulosin 0.4-mg group and placebo group, respectively, and there was no statistically significant or clinically meaningful difference among the groups. The mean change in DBP associated with the orthostatic tests during the administration period was +2.4 -+3.6 mmHg, +2.6 -+3.4 mmHg and +3.3 -+4.4 mmHg in the tamsulosin 0.8-mg group, tamsulosin 0.4-mg group and placebo group, respectively. There was a marginally statistically significant difference in DBP observed 1 week after initiation of administration (+3.1, +4.5 and +3.9 mmHg for the tamsulosin 0.8-mg group, tamsulosin 0.4-mg group and placebo group, respectively; P = 0.055), but since the magnitude of the difference between the placebo and treatment groups was < 1 mmHg, treatment with tamsulosin was not considered to cause any clinically meaningful change in DBP.
At baseline and all subsequent visits, < 1% of patients in the tamsulosin 0.8-mg group and 0.4-mg group met the third positive orthostatic test criterion (Table 1) . No patient in the placebo group met this criterion at baseline or any other visit. There was no statistically significant difference in the percentage of patients in the tamsulosin groups who met the third criterion.
The mean change in PR during the baseline orthostatic test was +6.0 bpm, +5.1 bpm and +5.3 bpm in the tamsulosin 0.8-mg group, tamsulosin 0.4-mg group and placebo group, respectively. There was no statistically significant difference among the groups. The mean change in PR during the treatment period was +5.5 -+6.5 bpm, +4.6 -+6.3 bpm and +4.6 -+5.9 bpm, respectively, in the 0.8-mg group, tamsulosin 0.4-mg group and placebo group. The mean change in PR associated with postural change that occurred in the tamsulosin groups was identical to that in the placebo group, and no patient showed any clinically meaningful change.
No patient in any group met the fourth positive orthostatic test criterion (Table 1) during the study.
The percentage of study subjects who met any criteria for a positive orthostatic test (Table 1) was 2 -5% in the tamsulosin 0.8-mg group, 2 -4% in the tamsulosin 0.4-mg group and 1 -3% in the placebo group (Fig. 5 ). There was no statistically significant difference in the percentage of K Yasukawa, H Swarz, Y Ito Safety of tamsulosin in orthostatic hypotension patients who met one criterion among the groups at any visit. No patient displayed symptoms indicative of clinically significant OH during the course of the study. The results obtained in US93-01 were consistent with those obtained in US92-03A.
Discussion
The effects of tamsulosin on the cardiovascular system on standing have been investigated more extensively than those of any other α-adrenoceptor antagonist. 33 In order to investigate the hypothesis that clinically efficacious doses of tamsulosin would produce minimum cardiovascular side-effects and OH compared with placebo, two large-scale, multicentre US phase III clinical trials, US92-03A and US93-01 were undertaken. These trials involved extensive orthostatic testing, close surveillance of symptoms and regular blood pressure and PR measurement over periods of 13 weeks. 13, 15 Methodology for the measurement of orthostatic blood pressure and PR has not been standardized, but methods used in these trials 13, 15 were similar to those published in several reports. 21,23 -26 Furthermore, the criteria for reduction in SBP and DBP in the definition of OH applied in the studies 13, 15 
Week (n) K Yasukawa, H Swarz, Y Ito Safety of tamsulosin in orthostatic hypotension coagulation system. Evaluation of SBP is considered to be important in consideration of the age group of BPH patients and comorbidity.
The data from the phase III trials suggest that tamsulosin in the treatment of BPH is associated with low risk for the development of OH, as the frequency of positive tests in the tamsulosin 0.4-mg and 0.8-mg groups was almost equal to those in the placebo group. Although there was an isolated statistically significant difference in the incidence of positive orthostatic test among the three study groups in US92-03A at first test agent administration, there was also a statistically significant difference observed at baseline. We cannot conclude to what extent the difference in patient characteristics influenced the results of measurements after test agent administration, because the frequently met test criterion was different before and after administration.
Both US92-03A and US93-01 were conducted without an active control group with a known risk of OH. Compared with placebo, the two clinical trials demonstrated consistently that treatment with tamsulosin was associated with a similar incidence of orthostatic tests in patients recruited to the study. The question remained, however, that the orthostatic test used in the studies may not be sensitive enough to detect the potential effects of tamsulosin or other α-antagonists on postural changes.
Studies comparing tamsulosin with conventional α 1 -antagonists, which have lower receptor selectivity than that of tamsulosin, have been conducted using similar methods of orthostatic testing to investigate the possible difference in incidence of OH. 33,42 -44 In a double-blind, double-dummy, randomized, parallel-group study comparing the recommended regimens of 15-day tamsulosin 0.4 mg once daily after breakfast or a step-up regimen of terazosin 1 mg, 2 mg and 5 mg administered once daily in the evening with placebo in elderly men, 43 orthostatic testing was carried out in a manner similar to that employed in the US clinical trials of tamsulosin. 13, 15 In the study, subjects with any active disease other than BPH and subjects prone to OH were excluded. Blood pressure and PR were measured 2 min after standing. Nine of 25 subjects receiving terazosin experienced 10 symptomatic OH events (defined as SBP decrease > 20 mmHg upon standing accompanied by dizziness, lightheadedness or syncope), of which five occurred after the 1 mg dose, which is lower than the clinically efficacious dose for BPH. Only one patient receiving tamsulosin, who had a previous history of vertigo, experienced such an event. Twelve subjects receiving terazosin experienced 24 asymptomatic OH events (defined as SBP decrease > 20 mmHg upon standing) compared with 12 events in seven subjects receiving tamsulosin. The sensitivity of the orthostatic test therefore appears adequate to detect the difference in orthostatic effect of the two α 1 -antagonists. The clear difference in the incidence of symptomatic OH between the terazosin and tamsulosin groups suggests that it is important to include positive test criteria with clinical symptoms in future studies.
The incidence of clinically significant OH was investigated to assess further each patient's risk of developing more severe orthostatic symptoms such as syncope or falling. In over 5000 assessments carried out in approximately 1000 patients, only three incidents categorized as clinically significant OH were observed; two in patients in the tamsulosin 0.8-mg group and one in the tamsulosin 0.4-mg group. Administration of tamsulosin did not K Yasukawa, H Swarz, Y Ito Safety of tamsulosin in orthostatic hypotension increase the incidence of clinically significant OH.
Post-marketing surveillance (pharmacovigilance) data on tamsulosin provide a useful comparison with the safety profile predicted for the drug based on orthostatic testing during US92-03A and US93-01. Long-term (up to 4-year) post-marketing surveillance trials, carried out under international legal requirements for the earliest possible detection of any unexpected adverse clinical effects, have indicated that the risk of spontaneous clinical events is not affected by tamsulosin treatment. An observational cohort study, using prescription event monitoring, examined clinical outcome data obtained by questionnaire from the prescribers on all (12 484) patients prescribed tamsulosin in the UK between June 1996 and January 1998 (80 508 patient-months of drug exposure). 45 The investigators concluded that although adverse events categorized as hypotension were among the most frequent (7.1 reports/ 1000 patients), the incidence was markedly low over the total treatment period (1.1 reports/1000 patient-months of treatment), even in the first month of treatment (4.2 reports/1000 patient-months of treatment).
A periodical safety update summarizing worldwide clinical safety data for tamsulosin between 1 July 1998 and 30 June 1999, which included 6684 patients treated in clinical trials, over 18 000 patients treated in observational programmes and the earlier UK results, showed no increase in reports of OH and hypotension relative to the population exposed (10 reports in total to 516 773 725 patient-days of treatment, based on one capsule of any dosage being equal to 1 patient-day of treatment). 17 Of the 10 reports, one case was not assessable with respect to cause. The frequency of OH is reported to be as high as 10 -20% among the community-dwelling elderly, 19, 20 therefore it can be concluded that the risk of OH does not increase with administration of tamsulosin to any clinically relevant degree. The results of these extensive safety assessments confirm that tamsulosin treatment is associated with a low incidence of OH and suggest that the orthostatic test used in US92-03A and US93-01 is a useful extrapolative method to evaluate the safety of a drug at the clinical investigation stage.
In conclusion, there is very low risk of OH in the treatment of BPH with tamsulosin 0.4 mg or 0.8 mg. From the low percentage of patients who met any of the four criteria for a positive orthostatic test during these studies, tamsulosin treatment is not considered to cause a clinically significant increase in the incidence of any criterion. The orthostatic test method and positive test criteria used in US92-03A and US93-01, particularly the combination of a positive orthostatic test and clinical symptoms of OH, were useful for evaluating the potential risk of OH during treatment with tamsulosin. The results of both phase III studies were consistent with the adverse-events profile reported in the post-marketing surveillance study, 45 and tamsulosin has been shown to exhibit a lower risk of OH in comparison with a less selective α 1 -antagonist. These findings suggest that the orthostatic test can be used in future clinical trials involving α 1 -antagonists and other drugs that present a risk of OH. 
